The role of brain dystrophin in muscular dystrophy; Implications for clinical care and translational research
- Version 249
- Download 1
- File Size 4.00 KB
- File Count 1
- Create Date 29 November 2019
- Last Updated 25 November 2022
Location: Hoofddorp, The Netherlands
Title: 249th ENMC workshop on The role of brain dystrophin in muscular dystrophy: implications for clinical care and translational research
Date: 29th November-1st December 2019
Organisers: Dr J. Hendriksen (the Netherlands), Dr. M. Thangarajh (USA), Dr H.E. Kan (the Netherlands) and Prof F. Muntoni (UK)
Translations of this report by:
German by Prof U Schara
French by Dr C. Vaillend
Italian by Prof. A. Ferlini
Danish by Prof J. Vissing
Dutch by Dr M. van Putten and Dr N. Doorenweerd
Participants: Dr Y. Aoki (Japan), Dr P. Collin (the Netherlands), Dr M. Colvin (USA), Dr N Doorenweerd (the Netherlands), Prof A. Ferlini (Italy), Dr A. Goyenvalle (France), Dr J. Hendriksen (the Netherlands), Dr J. Hoskin (UK), Dr H.E. Kan (the Netherlands), Mr F. Lamy (France), Dr K. Maresh (UK), Prof F. Muntoni (UK), Dr E.H. Niks (the Netherlands), Prof U. Schara (Germany), Prof D. Skuse (UK), Prof V. Straub (UK), Prof S. Takeda (Japan), Dr M. Thangarajh (USA), Dr N. Truba (USA), Prof S. Tyagarajan (Switzerland), Dr C. Vaillend (France), Dr M. van Putten (the Netherlands), Prof J. Vissing (Denmark), Dr E. Vroom (the Netherlands).
The 249th ENMC workshop was held from the 29th of November to the 1st of December 2019, and brought together 24 representatives of patients, neuromuscular, neuropsychology, and psychiatry experts from Europe, the United States, and Japan. The topic of this workshop was the brain comorbidities in Duchenne and Becker muscular dystrophies (DMD and BMD respectively).
The molecular basis of the brain involvement present in patients with DMD and BMD is increasingly being unravelled. We now appreciate that cognitive, behavioural, and psychiatric symptoms may affect up to approximately 50% of individuals with DMD, and recent evidence indicates a high prevalence of brain comorbidities in patients with BMD, as well. This finding is related to the deficiency of multiple dystrophin variants, also called isoforms, during brain development in different brain locations. These central nervous system (CNS) symptoms have important clinical implication for the affected individuals and their full participation in life; more importantly, these CNS symptoms are often not well recognised and managed adequately in clinical settings. Moreover they are not addressed by the genetic therapies under development, as these treatment approaches mainly aim to improve skeletal and heart muscle function and do not target the brain of the patients.
The topics discussed during the three day workshop encompassed experimental and clinical aspects relevant for dystrophin in the brain. Regarding the experimental and preclinical aspects, we discussed: i. the genetic regulation of the various forms of dystrophin in the brain, and their distribution in different brain regions, drawing attention to similarities and differences between the human and mouse models; ii) which are proteins that interact with the different forms of dystrophin in different areas of the brain; iii) which are the behavioural and structural correlates in different mouse models with genetic changes that differently disrupt the different forms of dystrophin in the brain and how does this change over time; iv) the effect of restoring different forms of dystrophin after birth using different genetic therapies. Regarding the clinical topics, we discussed: i) what is the frequency and severity of brain related symptoms in DMD/BMD; ii). what can brain imaging telling us about the features of dystrophin deficiency (both in DMD and BMD patients)); iii) what can the human symptoms teach us to direct the deeper assessment of the mdx mouse models deficient in the various forms of dystrophin, and vice-versa, what are emerging features from the studies in the mice that should be explored further in patients; iv). What are the recommended standards of care for the assessment and management of CNS symptoms; v) what are the treatment options to improve the outcome of DMD/BMD patients in whom neuropsychiatric symptoms occur?
The representatives from patient advocacy groups’ elegantly articulated how common and significant the cognitive symptoms are in affected individuals, and highlighted the extra burden for the families that these symptoms cause. Too often the neuromuscular specialists concentrate exclusively on the muscle and heart complications, with little attention to the early diagnosis and intervention for the brain problems. It is encouraging that at least some of the behavioural aspects of DMD can be improved by medication, but these therapies are not systematically utilised; and much more research to investigate the underlying mechanisms for the CNS symptoms is required, in order to find more specific interventions.
The participants’ agreed to collaborate further regarding patient registries, experimental models, and clinical studies on these topics and specific working groups were formed to address specific areas. This collaboration will also be facilitated by the recently awarded European Union H2020 grant to address the Brain Involvement iN Dystrophinopathies (BIND) which will begin in January 2020. A full report of the conference is published in Neuromuscular Disorders.
ENMC
Lt. generaal van Heutszlaan 6
3743 JN BAARN
The Netherlands
+ 31- 35-5480481
enmc@enmc.org
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy